Novel targets
Multiple modalities
Vast potential
We develop first-in-class and best-in-class medicines for hard-to-treat cancer and Alzheimer’s disease.
Leveraging innate and adaptive immune checkpoints—CTLA-4, CD24, and Siglec—we have the potential to target cancer cells and boost immune response like never before.
Our scientific approach
From pioneering research to developing next-generation therapeutics, we are poised to make cancer therapies safer, more effective, and more durable.
PD-1/VEGF bispecific program
CTLA-4 program
A new and enduring generation of CTLA-4 antibody therapy is here. Discover how gotistobart, currently partnering with BioNTech, is poised to change the treatment of patients with immunotherapy-resistant non–small cell lung cancer and other advanced tumors.
Learn about our CTLA-4 program
Siglec programs
Siglecs play a crucial role in mediating our body’s immune response through cell-cell interaction and communication. We’re working to target Siglec signaling to unleash cancer immunity and normalize microglia function to protect against neurodegeneration associated with immunotherapy, ADC’s, and other cancer treatments.
Learn about our Siglec programs
CD24 platform
CD24 is overexpressed in approximately 70% of human cancers, yet its presence on normal tissues has long posed a challenge to targeting CD24 for cancer treatment. See how our cancer-selective anti-CD24 antibody may help to over this challenge.
Learn about our CD24 platform
Pipeline
Fighting cancer and Alzheimer’s disease demands an arsenal of therapeutic approaches. That’s why we’re engineering medicines that leverage a diverse array of modalities, including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and CAR T-cell therapies. Discover what we have in our pipeline.
Join our team
Interested in joining a smart and collaborative team that’s changing how medicine treats the toughest cancers? Explore our job openings and get in touch.